$RVV $RVVTF - Great Post on Yahoo ! James - Thank U !!“Finally”, we’re getting somewhere!, there’s no better way to gain credibility or support for Bucillamine than to allow a University such as the University of California, San Francisco (“UCSF”) to explore the efficacy of Bucillamine as a treatment for severe COVID-19, it’s quite obvious to me that the 3rd phase of this journey for the treatment of mild to moderate COVID has done well for REVIVE TO even entertain the idea of exploring the utility of Bucillamine as a severe treatment for COVID-19, I really don’t care what anyone else has to say, I just want to see “results”, because this has been such a long and drawn out process, for a proven safe 30 year old anti inflammatory drug that under these unprecedented circumstances should have flew through the testing process as government should have backed this as well!!, Revive has been lobbying the FDA from the very beginning to be fast tracked!!, not once has the Canadian or US government shown any significant “if any” support at all!, I started buying shares in RVV.CN as a psychedelic play to which probably would have done much better without Bucillamine as a distraction!?, many fantastic breakthroughs and data have come through Revive Therapeutics amazing pipeline, this is a cannibinol/psychedelic company that has pioneered many breakthroughs especially in the development of Cannabidiol ( CBD) for the treatment of many rare diseases like autoimmune hepatitis a rare liver disease in the prevention of ischemia and reperfusion injury resulting from organ transplants such as liver, heart, kidney and lung. their work with psychedelics from treatments to delivery systems have all been unprecedented as their pipeline continues to grow and they continue to ramp up clinical trials and phases. It’s seems that with all their advances and breakthroughs are continuously canceled out by the hype and focus that’s been placed solely on their phase 3 clinical testing!!. On a positive note, their BUCILLAMINE treatments must be doing quite well and satisfying all the end points or they wouldn’t have pursued another research agreement!!, when this finally does come to a head it should all unfold in stages, mild to moderate approval to severe approvals for treatment of the COVID-19 virus, Face it there’s a lot sick people out there that will continue to get sick from this virus, many who have made it through are still left with lung damage or breathing problems, bucillamine showed promise in treating patients with these residual symptoms and effects, hopefully bucillamine is given FDA and Health Canada approval soon so that people can get on with their life and we as patient long investors can move on with ours!!, still bullish and still think investors will be pleasantly surprised by the final outcome!, I think at this point and I don’t blame them, but Revive Therapeutics just wants to cross all their t’s” and dot all their “I”s making sure that all the bases have been covered. GLTA!!